GSTM1 and Schnyder corneal dystrophy: Seven SCD patients with data remained vaso-occlusion event-free 5–22 months post-gene-editing therapy with total Hb ranging from 11.0–15.9 g/dL and HbF from 39.6–49.6% at the last visit [140].